These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18035560)

  • 21. Gaucher mutation N188S is associated with myoclonic epilepsy.
    Kowarz L; Goker-Alpan O; Banerjee-Basu S; LaMarca ME; Kinlaw L; Schiffmann R; Baxevanis AD; Sidransky E
    Hum Mutat; 2005 Sep; 26(3):271-3; author reply 274-5. PubMed ID: 16086325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).
    Hruska KS; LaMarca ME; Scott CR; Sidransky E
    Hum Mutat; 2008 May; 29(5):567-83. PubMed ID: 18338393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gaucher type 2 disease: identification of a novel transversion mutation in a French-Irish patient.
    Choy FY; Humphries ML; Ben-Yoseph Y
    Am J Med Genet; 1998 Jun; 78(1):92-3. PubMed ID: 9637431
    [No Abstract]   [Full Text] [Related]  

  • 24. Identification of a novel mutation, I403T, in Cuban type 1 Gaucher disease.
    Lavaut K; Rubio T; Collazo T; Esperón AA; Reyes L; Collazo T; Acanda AM
    Blood Cells Mol Dis; 2011 Apr; 46(4):327. PubMed ID: 21411350
    [No Abstract]   [Full Text] [Related]  

  • 25. Divergent phenotypes in Gaucher disease implicate the role of modifiers.
    Goker-Alpan O; Hruska KS; Orvisky E; Kishnani PS; Stubblefield BK; Schiffmann R; Sidransky E
    J Med Genet; 2005 Jun; 42(6):e37. PubMed ID: 15937077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    Zimran A; Neudorfer O; Elstein D
    N Engl J Med; 2005 Feb; 352(7):728-31; author reply 728-31. PubMed ID: 15719452
    [No Abstract]   [Full Text] [Related]  

  • 27. Type 2 gaucher disease: an expanding phenotype.
    Tayebi N; Stone DL; Sidransky E
    Mol Genet Metab; 1999 Oct; 68(2):209-19. PubMed ID: 10527671
    [No Abstract]   [Full Text] [Related]  

  • 28. Four Gaucher disease type II patients with three novel mutations: a single centre experience from Turkey.
    Bulut FD; Kör D; Şeker-Yılmaz B; Hergüner Ö; Ceylaner S; Özkınay F; Kılavuz S; Önenli-Mungan N
    Metab Brain Dis; 2018 Aug; 33(4):1223-1227. PubMed ID: 29656334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gaucher disease.
    Butters TD
    Curr Opin Chem Biol; 2007 Aug; 11(4):412-8. PubMed ID: 17644022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Look before you leap. Carrier screening for type 1 Gaucher disease: difficult questions.
    Borry P; Clarke A; Dierickx K
    Eur J Hum Genet; 2008 Feb; 16(2):139-40. PubMed ID: 18043719
    [No Abstract]   [Full Text] [Related]  

  • 31. Gaucher disease in South Africa.
    Heitner R
    S Afr Med J; 2008 Jan; 98(1):11-2. PubMed ID: 18270627
    [No Abstract]   [Full Text] [Related]  

  • 32. Gaucher disease phenotypes outflanked?
    Beutler E
    Genome Res; 1997 Oct; 7(10):950-1. PubMed ID: 9331364
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacologic chaperoning as a strategy to treat Gaucher disease.
    Yu Z; Sawkar AR; Kelly JW
    FEBS J; 2007 Oct; 274(19):4944-50. PubMed ID: 17894779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simplified detection of Nci mutation in Gaucher disease.
    Dahl N; Lagerström M; Erikson A; Pettersson U
    Lancet; 1990 Jun; 335(8705):1589-90. PubMed ID: 1972504
    [No Abstract]   [Full Text] [Related]  

  • 35. D409H/D409H genotype in Gaucher-like disease.
    Uyama E; Uchino M; Ida H; Eto Y; Owada M
    J Med Genet; 1997 Feb; 34(2):175. PubMed ID: 9040001
    [No Abstract]   [Full Text] [Related]  

  • 36. [Gaucher disease].
    Ida H
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):356-9. PubMed ID: 9645082
    [No Abstract]   [Full Text] [Related]  

  • 37. Gaucher disease and parkinsonism.
    Sidransky E
    Mol Genet Metab; 2005 Apr; 84(4):302-4. PubMed ID: 15781189
    [No Abstract]   [Full Text] [Related]  

  • 38. Gaucher disease type 2: homozygosity for the mutation F331S in two unrelated consanguineous Muslim Arab patients with Gaucher disease from the Gaza and Jenin regions.
    Baris HN; Raas-Rothschild A; Garty BZ; Tor R; Klontz S; Tayebi N; Sidransky E; Cohen IJ
    Blood Cells Mol Dis; 2011 Dec; 47(4):262-3. PubMed ID: 21889374
    [No Abstract]   [Full Text] [Related]  

  • 39. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.
    Sánchez-Ollé G; Duque J; Egido-Gabás M; Casas J; Lluch M; Chabás A; Grinberg D; Vilageliu L
    Blood Cells Mol Dis; 2009; 42(2):159-66. PubMed ID: 19167250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
    Wang GN; Reinkensmeier G; Zhang SW; Zhou J; Zhang LR; Zhang LH; Butters TD; Ye XS
    J Med Chem; 2009 May; 52(10):3146-9. PubMed ID: 19397268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.